CONTENTS

Cited in: (Printed/On-line): Addiction Abstracts; Biological Abstracts/BIOSIS; Bibliographic Internationale/PASCAL; Elsevier/BIOSBASE/Current Awareness in Biological Sciences (CABS); Chemical Abstracts/CA SEARCH; /Life Sciences Collection; Current Contents/Current Contents Search; Excerpta Medica/EMBASE; Index Medicus/MEDLINE; Science Citation Index/SciSearch; Social Science Citation Index/Social SciSearch; Sociological Abstracts/Sociological Abstracts; Toxline; HealthSTAR; Psychological Abstracts/PsychINFO; ETOH/ISI/ELSEVIER
Clinical Medicine Citation Index; Research Alert/Research Alert Direct; TOXIBASE

Editorial
Foreword to: Buprenorphine and buprenorphine/naloxone: a guide for clinicians
P.J. Fudala, T.P. Bridge .................................................................................................................. S1

Reviews
From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States
J.H. Jaffe, C. O'Keeffe .................................................................................................................. S3
The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic
S.L. Walsh, T. Eissenberg .............................................................................................................. S13
Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?
J. Mendelson, R.T. Jones .............................................................................................................. S29
Pharmacokinetics of the combination tablet of buprenorphine and naloxone
C.N. Chiang, R.L. Hawks .............................................................................................................. S39
Clinical efficacy of buprenorphine: comparisons to methadone and placebo
W. Ling, D.R. Wesson .................................................................................................................. S49
Buprenorphine: how to use it right
R.E. Johnson, E.C. Strain, L. Amass .......................................................................................... S59
Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence
T.P. Bridge, P.J. Fudala, S. Herbert, D.B. Leiderman ................................................................ S79
Use of buprenorphine in pregnancy: patient management and effects on the neonate
R.E. Johnson, H.E. Jones, G. Fischer .......................................................................................... S87

Commentary
Accessing opiate dependence treatment medications: buprenorphine products in an office-based setting
A.L. Leshner .................................................................................................................................. S103

This journal is part of ContentsDirect, the free alerting service which sends tables of contents by e-mail for Elsevier Science books and journals. You can register for ContentsDirect online at: http://contentdirect.elsevier.com

Also available on
www.sciencedirect.com